The GIFT Nifty futures, which is an early indicator of the Nifty50 index, was trading 0.23% higher by 60.50 points at 25,901 indicating that the domestic benchmark indices are likely to make a positive start on Monday. 

On Friday, 20 September, Domestic benchmark indices S&P BSE Sensex soared 1,359.52 points or 1.63% to end at 84,544.31 while the Nifty50 traded 375.15 points higher or 1.48% and settled at 25,790.95.

Here are some stocks that are likely to remain in focus on 23 September.

HDFC Bank: The bank’s subsidiary, HDB Financial Services is planning for an initial public offering (IPO), including a fresh issue of Rs 2,500 crore along with an offer for sale by existing and eligible shareholders. 

Vodafone Idea: The company has finalised a Rs 30,000 crore ($3.6 billion) deal with Samsung, Nokia, and Erikson to supply network equipment over three years. This deal is the first step in the company’s transformative three-year capital expenditure plan, which is valued at $6.6 billion (Rs 55,000 crore).

Adani Total Gas: The company has secured a $375 million financing package from global lenders, making this the largest global funding initiative in the city gas distribution business. 

HFCL: The company has signed a strategic partnership with General Atomics Aeronautical Systems Incorporated (GA-ASI) for developing and supplying critical sub-systems for GA-ASI’s advanced Unmanned Aircraft Systems (UAS). 

Spicejet: The Board of Directors of the company have approved the issuance and allotment of 48.7 crore equity shares to qualified institutional buyers at the price of Rs 61.60 per share, which includes a premium of Rs 51.60 and a discount of Rs 3.19 per share to the floor price. 

ONGC: The company’s subsidiary, ONGC Videsh, has signed a non-associated gas agreement for the Azeri-Chirag-Deepwater Gunashili (ACG) field in Azerbaijan. 

Glenmark Pharma: The USFDA conducted a a Good Manufacturing Practice (GMP) inspection at the company’s formulation manufacturing facility in Chhatrapati Sambhaji Nagar (Aurangabad), between 9 September and 20 September, and concluded the inspection with zero observation. 

Aarti Drugs: The company’s API manufacturing facility in Tarapur, Maharashtra, received seven observations after the US Food and Drug Administration (USFDA) conducted an inspection between 12 September and 20 September. 

Mankind Pharma: The company Board has approved raising up to Rs 10,000 crore by issuing non-convertible debentures (NCDs) and commercial papers on a private placement basis.

Discover the next big investment! Unicorn Signals’ IPO screener helps you identify promising initial public offerings. Download Unicorn Signals and get ahead of the curve! Sign Up Now & Find Your Next IPO Gem!